Drug products: Daonil®, Glibenklamid Recip
ATC code: A10BB01
Controlled studies on difference between men and women in effect of glicenclamide are lacking, except for hyperglycemia in combination with stroke.
While some studies indicate that women have a higher risk of hypoglycemia during antidiabetic treatment than men, other smaller studies have not found any differences between men and women in the risk of hypoglecemia during glibenclamide treatment.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of glibenclamide have been found.
A study investigated whether the use of glibenclamide both at the time of stroke and during hospitalization result in better neurological and functional outcomes in patients with diabetes mellitus. Improvements occurred in patients with nonlacunar strokes and were independent of sex .
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment .In a study of 57 reported cases of glibenclamide-associated hypoglycemia to the Swedish Adverse Drug Reactions Advisory Committee in 1983, there was a female preponderance (61%). However, no adjustments for proportion women and men prescribed glibenclamide were made, which makes the results difficult to interpret. Sex did not predict the clinical course of the hypoglycemic events . A small retrospective case-control study of prolonged hypoglycemia in patients (5 men, 2 women) with end-stage renal disease and type 2 diabetes receiving glibenclamide found no association between risk of hypoglycemia and sex .
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
An observational retrospective study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with type 2 diabetes. Sex had no significant influence on change in body weight or BMI .
Date of litterature search: 2014-06-03
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson